Recent ARVN News
- Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress • GlobeNewswire Inc. • 05/09/2024 08:42:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 08:13:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 11:02:45 AM
- Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/07/2024 11:00:11 AM
- Arvinas to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer • GlobeNewswire Inc. • 04/24/2024 08:30:38 PM
- Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer • GlobeNewswire Inc. • 04/11/2024 11:00:49 AM
- Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer • GlobeNewswire Inc. • 03/18/2024 08:40:46 PM
- Arvinas to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 03/04/2024 12:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:35:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:34:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:33:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:33:04 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/27/2024 09:46:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 12:02:59 PM
- Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/27/2024 12:00:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 09:06:49 PM
- Arvinas Announces Chief Financial Officer Transition • GlobeNewswire Inc. • 02/20/2024 09:05:04 PM
- Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease • GlobeNewswire Inc. • 02/20/2024 12:00:44 PM
- Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer • GlobeNewswire Inc. • 02/14/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:14:06 AM
- Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer • GlobeNewswire Inc. • 02/06/2024 11:45:00 AM
- Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference • GlobeNewswire Inc. • 02/01/2024 09:30:20 PM
- Arvinas Appoints Jared Freedberg as General Counsel • GlobeNewswire Inc. • 01/16/2024 10:01:06 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/16/2024 09:03:03 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM